Axogen Inc vs Ford Motor Company — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while Ford Motor Company trades at $13.84 (market cap $55.75B). The key difference: Ford Motor Company is far larger — about 21.4× Axogen Inc's market cap, and Ford Motor Company pays a 4.29% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | F | |
|---|---|---|
Market Cap | $2.61B | $55.75B |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $17.44 |
52-Week Low | $14.16 | $11.21 |
Enterprise Value | $2.52B | $187.71B |
Dividend Yield | — | 4.29% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →